India currently does not have any XBB 1.5 variant-based vaccines available. IMAGE: A healthcare worker prepares a dose of a COVID-19 vaccine. Photograph: ANI Photo New-generation Covid......
Vaccine makers in India have a limited stockpile of doses, even as COVID-19 threatens to rear its head this winter season, reports Sohini Das. IMAGE: A beneficiary is being inoculated with a......
IMAGE: Adar Poonawalla, CEO, Serum Institute of India. Photograph: ANI Photo With only 146 sites conducting vaccinations in India and a few hundred vaccine shots administered every day,......
In view of rising cases of COVID-19 in various parts of the country, Union Health Minister Mansukh Mandaviya is learnt to have approved the inclusion of Serum Institute's Covovax on the CoWIN......
Serum Institute of India (SII) and Bharat Biotech have also stopped producing the Covishield and Covaxin vaccines respectively. IMAGE: A healthcare worker collects a swab sample for Covid-19 test,......
India's willingness to play a big role in the manufacturing and to allow some of those vaccines to go to other developing countries will be an absolutely critical part of containing the pandemic,......
Serum Institute of India plans to make 300 million doses of AZD1222 by December, and will begin phase-2 trials soon. It has also tied up with Novavax for development and commercialisation of its......
'Once the trials are successful in India and the UK, we are certain that COVISHIELD will be one of the first vaccines to be introduced.' IMAGE: The Reference Center for Special Immunobiologicals......
Members of industry chamber Confederation of Indian Industry have signed eight memoranda of understandings with American companies. The signing of agreements coincides with Prime Minister Manmohan......
Six Indian companies, including Tata Communications and Infosys Technologies, have signed separate agreements in Washington with US-based companies to enhance cooperation, coinciding with the state......